List of Excipients in Branded Drug FLUTICASONE

« Back to Dashboard

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Prasco Laboratories	FLUTICASONE FUROATE AND VILANTEROL	fluticasone furoate and vilanterol	66993-135	LACTOSE MONOHYDRATE	2026-05-13
Prasco Laboratories	FLUTICASONE FUROATE AND VILANTEROL	fluticasone furoate and vilanterol	66993-135	MAGNESIUM STEARATE	2026-05-13
Prasco Laboratories	FLUTICASONE FUROATE ELLIPTA	fluticasone furoate	66993-166	LACTOSE MONOHYDRATE	2026-03-01

Generic Drugs Containing FLUTICASONE

Company	Ingredient	NDC	Excipient
Unit Dose Services	fluticasone propionate	50436-2640	ANHYDROUS DEXTROSE
Unit Dose Services	fluticasone propionate	50436-2640	BENZALKONIUM CHLORIDE
Unit Dose Services	fluticasone propionate	50436-2640	CARBOXYMETHYLCELLULOSE SODIUM

What are the Most Frequently-Used Excipients in FLUTICASONE?

# Of NDCs	Excipient
7	ANHYDROUS DEXTROSE
8	BENZALKONIUM CHLORIDE
8	CARBOXYMETHYLCELLULOSE SODIUM

Fluticasone Excipient Strategy and Commercial Opportunities

Last updated: October 6, 2026

Fluticasone is a platform molecule used in nasal sprays, inhaled corticosteroids, topical creams, lotions, ointments and combination respiratory products. The main commercial opportunities are differentiated delivery systems, preservative-free nasal formulations, lactose-controlled dry powders, suspension stability, device performance, pediatric dosing and combination products. Excipient patents are most valuable when they are tied to a measurable clinical, manufacturing or device advantage.

What fluticasone products require different excipient strategies?

Fluticasone is commercially used mainly as fluticasone propionate and fluticasone furoate. These forms are not interchangeable from a formulation, regulatory or patent perspective.

Product category	Representative active ingredient	Main dosage form	Primary excipient challenge
Nasal spray	Fluticasone propionate	Aqueous suspension	Particle suspension, spray plume, preservative exposure
Nasal spray	Fluticasone furoate	Aqueous suspension	Low-dose uniformity, suspension stability, device deposition
Metered-dose inhaler	Fluticasone propionate	HFA suspension	Particle size, valve delivery, propellant compatibility
Dry-powder inhaler	Fluticasone propionate or furoate	Carrier-based powder	Lactose blending, moisture control, powder deagglomeration
Topical dermatology	Fluticasone propionate	Cream, ointment, lotion or solution	Skin penetration, preservative system, irritation and rheology
Combination inhaler	Fluticasone propionate or furoate with a bronchodilator	DPI or MDI	Chemical compatibility and dose uniformity between actives

Fluticasone propionate has low aqueous solubility, so many nasal and inhaled products use suspended micronized particles rather than a true solution. That creates opportunities around particle morphology, wetting, sedimentation control and delivery-device calibration.

Which excipients are used in commercial fluticasone products?

Nasal suspension excipients

Fluticasone propionate nasal spray products commonly use microcrystalline cellulose and carboxymethylcellulose sodium as suspending and viscosity-modifying agents. Other common excipients include dextrose, polysorbate 80, benzalkonium chloride, phenethyl alcohol and purified water. The product label for Flonase lists this general excipient architecture.[1]

The formulation objectives are:

• Keep micronized fluticasone uniformly suspended between doses.
• Produce consistent metered volume and plume geometry.
• Prevent nozzle clogging.
• Control microbial growth in a multidose bottle.
• Limit irritation, burning and post-nasal drip.
• Maintain performance over the in-use period.

Benzalkonium chloride is commercially useful as a preservative but creates a differentiation opportunity for preservative-free products. Preservative-free packaging can command a premium where chronic users, pediatric patients or patients with nasal mucosal sensitivity prefer reduced excipient exposure.

Inhaled dry powders

Dry-powder inhalers commonly use lactose monohydrate as a carrier. The active drug is micronized and blended with larger lactose particles. Some platforms also use magnesium stearate or related surface-modifying excipients to improve powder dispersion and reduce adhesion.

For fluticasone, the critical variables are:

• Lactose particle-size distribution.
• Carrier surface roughness.
• Fine-particle lactose fraction.
• Active-to-carrier adhesion.
• Residual moisture.
• Blending energy and blend uniformity.
• Detachment of respirable fluticasone during inhalation.

The commercial product Flovent Diskus uses a dry-powder platform, while Arnuity Ellipta uses an Ellipta inhaler platform. Their labels identify lactose-containing excipients and, for some products, milk-protein-related labeling considerations.[2,3]

A lactose-free dry-powder platform would address a recognizable market segment, but it would require a technically credible alternative carrier or carrier-free dispersion system. Candidate approaches include engineered porous particles, phospholipid-based particles, amino-acid excipients and spray-dried composite particles. Each option would require inhalation toxicology, device compatibility and robust delivered-dose data.

HFA metered-dose inhalers

Fluticasone propionate HFA products use a hydrofluoroalkane propellant system. Flovent HFA is a representative product. The formulation must maintain suspension stability in the canister and deliver a reproducible dose through the metering valve and actuator.[4]

Key excipient and process variables include:

• Propellant selection and purity.
• Ethanol concentration, if used.
• Suspension sedimentation and redispersion.
• Valve gasket compatibility.
• Canister coating.
• Actuator orifice geometry.
• Spray temperature and plume characteristics.
• Extractables and leachables.

HFA products also face long-term pressure to reduce environmental impact from fluorinated propellants. A next-generation fluticasone MDI could pursue lower-global-warming-potential propellants, but the commercial opportunity depends on equivalence, device redesign, manufacturing conversion and regulatory bridging.

Topical formulations

Topical fluticasone propionate products use conventional dermatological vehicles, including creams, ointments, lotions and solutions. Excipient selection affects drug partitioning into the stratum corneum, occlusivity, patient feel and irritation.

The strongest opportunities are not simply new cream bases. More defensible platforms include:

• Low-irritancy vehicles for sensitive skin.
• Non-greasy lotions for scalp or large-area application.
• Foam or spray delivery for hairy or difficult-to-reach sites.
• Anhydrous formulations with improved stability.
• Preservative-free single-use packaging.
• Controlled-release topical systems.
• Vehicles that reduce systemic absorption while maintaining local activity.

FDA classifies fluticasone propionate as a high-potency topical corticosteroid in certain dosage forms. Formulation changes therefore require careful evaluation of local tolerability, hypothalamic-pituitary-adrenal-axis effects and comparative clinical performance.[5]

What excipient patents can protect fluticasone products?

Excipient patents rarely protect the excipient alone. Stronger claims cover the relationship between the excipient, active ingredient, device and performance result.

Potential claim categories include:

Patent category	Example claim focus	Commercial value
Suspension formulation	Viscosity range, wetting system, particle sedimentation profile	Medium to high
Nasal delivery	Preservative-free composition with defined plume or deposition	High
DPI carrier system	Lactose morphology, carrier coating or fine-particle fraction	High
MDI system	Propellant, ethanol, valve and particle-size relationship	High
Particle engineering	Crystalline form, morphology, surface treatment or aerodynamic diameter	High
Topical vehicle	Specific solvent, emulsifier, rheology and skin-flux profile	Medium
Device combination	Actuator, inhaler resistance or dose-counter integration	High
Manufacturing process	Milling, spray drying, blending or suspension homogenization	Medium to high
Stability package	Reduced degradation, improved in-use stability or container compatibility	Medium

A patent claiming only “fluticasone plus polysorbate 80” is likely to face substantial prior-art risk unless it defines a narrow concentration range and demonstrates an unexpected technical effect. Claims tied to delivered dose, fine-particle fraction, spray deposition, reduced nozzle clogging or improved stability are more commercially relevant.

What FDA regulatory status applies to fluticasone products?

Fluticasone products span prescription, over-the-counter and abbreviated approval pathways.

Product	Regulatory status	Reference product or pathway issue
Flonase nasal spray	OTC product	Consumer labeling, device performance and nasal-spray equivalence
Flovent HFA	Prescription inhaler	Generic MDI development and device-drug equivalence
Flovent Diskus	Prescription DPI	Device-specific inhalation equivalence
Arnuity Ellipta	Prescription DPI	Ellipta device and fluticasone furoate formulation
Xhance	Prescription nasal delivery system	Exhalation delivery device and local deposition
Generic topical fluticasone	Prescription or OTC depending on product	Vehicle, potency and therapeutic equivalence

The FDA’s product-specific guidance for orally inhaled and nasal drug products is important because conventional pharmaceutical equivalence does not by itself establish substitutability. Inhaled products require aerodynamic performance, delivered-dose uniformity, device operation and, depending on the product, comparative clinical or pharmacodynamic evidence.[6]

Xhance is commercially distinct because it combines fluticasone propionate with an exhalation delivery system intended to improve deposition in the nasal passages. The device is central to the product’s regulatory and patent position.[7]

What is the Orange Book status of fluticasone products?

The Orange Book records patents and regulatory exclusivities for eligible prescription drug products, but it does not provide a complete view of fluticasone intellectual property. OTC Flonase products are not analyzed in the same way as prescription NDA products.

For prescription fluticasone products, the relevant patent categories include:

• Active-ingredient or polymorph patents.
• Formulation patents.
• Inhaler or nasal-delivery patents.
• Method-of-use patents.
• Combination-product patents.
• Manufacturing patents.

Many early fluticasone propionate composition patents have expired or are no longer the primary barrier to generic entry. The more relevant barriers are product-specific device patents, formulation claims, regulatory requirements and manufacturing know-how.

A current Orange Book review should be performed at the individual NDA level for Flovent, Arnuity and Xhance because listed patents, delistings, pediatric exclusivities and litigation positions can change. The Orange Book itself is the controlling public source for listed patents and exclusivity data.[8]

When does fluticasone lose exclusivity?

Fluticasone does not have one universal loss-of-exclusivity date. The answer depends on:

1. The active moiety.
2. The salt or ester.
3. The dosage form.
4. The reference NDA.
5. The inhaler or nasal device.
6. Listed patents.
7. Regulatory exclusivity.
8. The jurisdiction.

Early fluticasone propionate products have faced generic competition for years. Generic nasal sprays and topical products are established in the United States. Inhaled products have been more difficult because the generic must match the drug-device combination, not only the active ingredient.

The practical exclusivity timeline is therefore segmented:

• Nasal fluticasone propionate: mature generic and OTC competition.
• Topical fluticasone propionate: mature generic competition, with differentiation shifting to vehicle and packaging.
• Fluticasone propionate MDI: device and formulation barriers remain more relevant.
• Fluticasone DPI: carrier, inhaler and equivalence requirements create higher development complexity.
• Fluticasone furoate products: later-generation products may retain stronger product-specific device and formulation positions.

Which companies are challenging fluticasone products?

Competition comes from several groups:

• Generic manufacturers developing nasal sprays and topical products.
• Respiratory companies developing generic or authorized-generic inhalers.
• Contract development and manufacturing organizations with inhalation capabilities.
• Device companies licensing inhaler or nasal-delivery platforms.
• Branded respiratory companies using fluticasone in combinations.

The most material competitive threats are likely to target mature fluticasone propionate products first. Fluticasone furoate and device-dependent products present greater technical and regulatory complexity, which can reduce the number of credible entrants.

Paragraph IV risk is product-specific. A generic applicant may challenge listed patents by asserting invalidity, noninfringement or unenforceability. For inhaled products, litigation risk can involve both pharmaceutical claims and device claims. The existence of a Paragraph IV filing does not guarantee an immediate launch because a 30-month stay, preliminary injunction, settlement or regulatory review can delay approval.[9]

What patent litigation and settlement issues affect fluticasone?

Fluticasone litigation typically falls into four categories:

1. Orange Book patent challenges against prescription inhalers.
2. Device patent disputes involving inhalers or nasal delivery systems.
3. ANDA litigation over topical or nasal formulations.
4. Trade-secret or manufacturing disputes involving particle engineering and blending.

Settlement agreements may include delayed entry, licenses, authorized-generic arrangements or restrictions tied to specific strengths and dosage forms. A settlement for one fluticasone product does not necessarily establish freedom to launch another product using the same active ingredient.

The most important diligence issue is claim scope. A patent covering a formulation may not block a technically distinct device. A device patent may not block a generic using a different actuator or inhaler. A method-of-use patent may have limited commercial impact if the generic label can omit the patented indication.

What commercial opportunities exist for fluticasone excipients?

1. Preservative-free nasal delivery

A preservative-free fluticasone nasal spray can target chronic users concerned about benzalkonium chloride and nasal irritation. The value proposition depends on maintaining microbial control through packaging, formulation and in-use testing.

2. Improved nasal deposition

Delivery systems that improve deposition in the posterior nasal cavity or sinus region can support premium positioning. The strongest opportunity combines a defined device geometry with pharmacodynamic or imaging evidence.

3. Lactose-free dry-powder inhalers

A lactose-free fluticasone DPI could address patients and prescribers seeking alternatives to lactose-containing products. The technical hurdle is achieving consistent aerosolization without compromising stability or manufacturability.

4. Low-global-warming-potential MDIs

Propellant transition creates an opportunity for reformulated fluticasone MDI products. Patent value may attach to the propellant, co-solvent, valve, canister, actuator and suspension process.

5. Pediatric and geriatric delivery

Lower-force actuators, dose counters, spacer-compatible systems and simplified priming can improve use in children and older adults. These features can support device patents and product-line extensions.

6. Topical vehicle differentiation

Foams, sprays, low-grease lotions and preservative-free packages offer practical commercial differentiation in dermatology. The largest opportunity is likely in patient adherence and application convenience rather than increased corticosteroid potency.

How strong is the fluticasone patent estate?

The estate is strongest where fluticasone is integrated with a proprietary device or technically narrow formulation. It is weaker for basic fluticasone propionate compositions and conventional topical vehicles.

Estate component	Relative strength
Basic fluticasone propionate composition	Low to medium
Mature nasal suspension	Low to medium
Proprietary exhalation nasal delivery	Medium to high
DPI carrier and inhaler combination	Medium to high
HFA reformulation	Medium to high
Conventional topical cream	Low
Specialized topical vehicle or packaging	Medium
Manufacturing and particle-engineering know-how	Medium, with trade-secret value

Geographic coverage differs materially. U.S. patent protection may be concentrated around Orange Book-listed claims, while European and other markets may rely on national validation, supplementary protection certificates, device claims and local regulatory exclusivity. Freedom-to-operate analysis must be conducted by product, dosage form and country.

What generic launch risks exist for fluticasone?

Generic launch risk is highest for mature nasal and topical products. It is more constrained for inhaled products because of:

• Device-specific equivalence requirements.
• Narrow therapeutic index concerns.
• Powder blend variability.
• Delivered-dose and aerodynamic performance requirements.
• Patent claims covering device operation.
• Manufacturing scale-up risk.
• Limited availability of specialized inhalation equipment.

A plausible launch sequence is:

Product type	Generic entry risk	Likely barrier
Topical fluticasone cream	High	Limited formulation differentiation
Nasal fluticasone spray	High	Device equivalence and suspension performance
HFA inhaler	Medium	Propellant, valve and device matching
Standard DPI	Medium	Carrier blend and inhaler performance
Exhalation nasal system	Low to medium	Proprietary delivery device and clinical evidence
Combination fluticasone inhaler	Medium	Multiple actives, device and patent layering

Key Takeaways

• Fluticasone is a multi-product platform, not a single formulation opportunity.
• Excipient value is highest when linked to delivery performance, device function or stability.
• Preservative-free nasal sprays, lactose-free DPIs and lower-impact MDIs are the clearest platform opportunities.
• Mature topical and nasal products face high generic pressure.
• Inhaled products remain more defensible because drug-device equivalence is technically demanding.
• Device patents, formulation claims and manufacturing know-how now matter more than basic fluticasone composition patents.
• Orange Book analysis must be performed by NDA, dosage form, strength and device.
• The best commercial candidates combine an excipient innovation with measurable patient, regulatory or manufacturing advantages.

FAQs

Can fluticasone be formulated without benzalkonium chloride?

Yes. A preservative-free nasal product can use sterile manufacturing, unit-dose packaging, multidose systems with microbial-control technology or alternative preservative approaches. The formulation must demonstrate acceptable in-use microbiological performance.

Is lactose essential in a fluticasone dry-powder inhaler?

No. Lactose is common because it supports carrier-based blending and dose uniformity, but engineered particles, phospholipid systems and other carriers may be used. Alternative systems require substantial inhalation performance and toxicology data.

Does changing the excipient create a new fluticasone patent?

Not automatically. Patentability usually requires a novel formulation or process with a non-obvious technical effect, such as improved stability, deposition, dose uniformity or tolerability.

Are fluticasone nasal sprays interchangeable across devices?

Not necessarily. The active ingredient may be the same while the suspension, actuator, spray plume, particle distribution and deposition profile differ. FDA equivalence requirements apply to the complete product system.

Which fluticasone product has the greatest licensing potential?

Proprietary nasal-delivery systems, inhaler platforms, low-global-warming-potential MDI technologies and lactose-free DPI systems have greater licensing potential than conventional cream or nasal-suspension excipients because they can support device claims, regulatory differentiation and manufacturing know-how.

References

1. U.S. Food and Drug Administration. (2023). Flonase Allergy Relief: Drug facts and prescribing information. FDA.

2. U.S. Food and Drug Administration. (2023). Flovent Diskus: Prescribing information. FDA.

3. U.S. Food and Drug Administration. (2023). Arnuity Ellipta: Prescribing information. FDA.

4. U.S. Food and Drug Administration. (2023). Flovent HFA: Prescribing information. FDA.

5. U.S. Food and Drug Administration. (2022). Topical corticosteroid labeling and safety information. FDA.

6. U.S. Food and Drug Administration. (2023). Draft guidance on orally inhaled and nasal drug products. FDA.

7. U.S. Food and Drug Administration. (2017). Xhance: Prescribing information. FDA.

8. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. FDA.

9. U.S. Food and Drug Administration. (2024). ANDA submissions: Refuse-to-receive standards and Paragraph IV certifications. FDA.